Dinutuximab beta, an immunotherapy drug administered to neuroblastoma patients, has been designated as an orphan drug.

Dinutuximab is a drug from EUSA Pharma, a domestic corporation launched last year, and is currently undergoing formal approval procedures. EUSA Pharma was absorbed and merged into Recordati in 2021. This drug is a chimeric antibody that targets a specific antigen called 'GD2' expressed on neuroblastoma cells. Dinutuximab beta is indicated for patients who previously received myelosuppression and hematopoietic stem cell transplantation and showed a partial response after receiving induction chemotherapy, and for patients with a history of relapsed or refractory neuroblastoma regardless o